NCT04549207View on ClinicalTrials.gov

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

April 17, 2025

Study Completion Date

June 30, 2026

Conditions
Breast CancerCastration-resistant Prostate Cancer
Interventions
DRUG

Bone modifying agent

Use of bone modifying agent

Trial Locations (5)

L6R 3J7

William Osler Health System, Brampton

N6A 5W9

London Health Sciences Centre, London

L3Y 2P9

Southlake Regional Health Centre, Newmarket

Unknown

The Ottawa Hospital Cancer Centre, Ottawa

P7B 6V4

Thunder Bay Regional Health Sciences Centre, Thunder Bay

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER